First Header Logo Second Header Logo

Connection

Herbert Bonkovsky to Antiviral Agents

Back to Details
This is a "connection" page, showing publications Herbert Bonkovsky has written about Antiviral Agents.
Herbert Bonkovsky
Connection Strength
5.173
Antiviral Agents
  1. Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome. World J Gastroenterol. 2014 Oct 21; 20(39):14142-55.
    View in: PubMed
    Score: 0.463
  2. Russo MW, Narang T, Eskind L, Hayes D, Casingal V, Purdum PP, Hanson JS, Ahrens W, Norton J, Bonkovsky H. Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci. 2013 Oct; 58(10):3010-6.
    View in: PubMed
    Score: 0.422
  3. Bonkovsky HL, Lambrecht RW, Naishadham D. Genetic variations in heme oxygenase-1 and chronic hepatitis. Hepatology. 2010 Jul; 52(1):400-1.
    View in: PubMed
    Score: 0.343
  4. Hou W, Tian Q, Zheng J, Bonkovsky HL. Zinc mesoporphyrin induces rapid proteasomal degradation of hepatitis C nonstructural 5A protein in human hepatoma cells. Gastroenterology. 2010 May; 138(5):1909-19.
    View in: PubMed
    Score: 0.328
  5. Bonkovsky HL, Tice AD, Yapp RG, Bodenheimer HC, Monto A, Rossi SJ, Sulkowski MS. Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration. Am J Gastroenterol. 2008 Nov; 103(11):2757-65.
    View in: PubMed
    Score: 0.301
  6. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci. 2008 Mar; 53(3):815-22.
    View in: PubMed
    Score: 0.283
  7. Bonkovsky HL, Stefancyk D, McNeal K, Banner BF, Liu Q, Zucker GM, Israel J, Stagias J, Colker J. Comparative effects of different doses of ribavirin plus interferon-alpha2b for therapy of chronic hepatitis C: results of a controlled, randomized trial. Dig Dis Sci. 2001 Oct; 46(10):2051-9.
    View in: PubMed
    Score: 0.187
  8. Szabo G, Katz E, Bonkovsky HL. Management of recurrent hepatitis C after liver transplantation: a concise review. Am J Gastroenterol. 2000 Sep; 95(9):2164-70.
    View in: PubMed
    Score: 0.174
  9. Bonkovsky HL, Woolley JM. Outcomes research in chronic viral hepatitis C: effects of interferon therapy. Can J Gastroenterol. 2000 Jul-Aug; 14 Suppl B:21B-29B.
    View in: PubMed
    Score: 0.172
  10. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 2000 Mar; 31(3):730-6.
    View in: PubMed
    Score: 0.168
  11. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999 Jan; 29(1):264-70.
    View in: PubMed
    Score: 0.155
  12. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug; 54(2):396-405.
    View in: PubMed
    Score: 0.092
  13. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR, Ghany MG. Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011 Apr; 53(4):1100-8.
    View in: PubMed
    Score: 0.090
  14. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar; 140(3):840-9; quiz e12.
    View in: PubMed
    Score: 0.088
  15. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep; 52(3):833-44.
    View in: PubMed
    Score: 0.087
  16. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK, Fontana RJ, Kranzler HR. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics. 2010 Mar-Apr; 51(2):137-48.
    View in: PubMed
    Score: 0.084
  17. Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr; 31(7):719-34.
    View in: PubMed
    Score: 0.083
  18. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009 Dec; 50(6):1719-26.
    View in: PubMed
    Score: 0.082
  19. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec; 137(6):1986-94.
    View in: PubMed
    Score: 0.081
  20. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun; 49(6):1828-37.
    View in: PubMed
    Score: 0.080
  21. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC, Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR, Chanock SJ, Chung RT, O'Brien TR. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology. 2009 Jun; 49(6):1847-58.
    View in: PubMed
    Score: 0.080
  22. Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug; 137(2):549-57.
    View in: PubMed
    Score: 0.079
  23. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 04; 359(23):2429-41.
    View in: PubMed
    Score: 0.077
  24. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009 Feb; 7(2):219-26.
    View in: PubMed
    Score: 0.077
  25. Morgan TR, Lambrecht RW, Bonkovsky HL, Chung RT, Naishadham D, Sterling RK, Fontana RJ, Lee WM, Ghany MG, Wright EC, O'Brien TR. DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol. 2008 Oct; 49(4):548-56.
    View in: PubMed
    Score: 0.074
  26. Sjogren MH, Sjogren R, Lyons MF, Ryan M, Santoro J, Smith C, Reddy KR, Bonkovsky H, Huntley B, Faris-Young S. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci. 2007 Jun; 52(6):1540-7.
    View in: PubMed
    Score: 0.069
  27. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML, Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG, Morishima C. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007 Feb; 5(2):245-54.
    View in: PubMed
    Score: 0.068
  28. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML, Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima C. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006 Dec; 44(6):1675-84.
    View in: PubMed
    Score: 0.067
  29. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RK, Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG, Gretch DR. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol. 2007 Mar; 46(3):420-31.
    View in: PubMed
    Score: 0.067
  30. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007 Jan; 132(1):103-12.
    View in: PubMed
    Score: 0.067
  31. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT, Lindsay KL, Lok AS, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Gretch DR. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology. 2006 Aug; 44(2):360-7.
    View in: PubMed
    Score: 0.065
  32. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie AM, Malet PF, Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis. 2006 Apr 01; 193(7):931-40.
    View in: PubMed
    Score: 0.063
  33. Bonkovsky HL, Salek J. No role of the -2518 promoter polymorphism of monocyte chemotactic protein-1 in chronic hepatitis C. Gastroenterology. 2005 Oct; 129(4):1361-2.
    View in: PubMed
    Score: 0.062
  34. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005 Aug; 42(2):282-92.
    View in: PubMed
    Score: 0.061
  35. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct; 25(5):472-92.
    View in: PubMed
    Score: 0.058
  36. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT, Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MG, Goodman ZD, Everhart JE. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004 Apr; 126(4):1015-23; discussion 947.
    View in: PubMed
    Score: 0.056
  37. Mathai J, Shimoda K, Banner BF, Mori M, Bonkovsky HL, Barnard GF. IFN-alpha receptor mRNA expression in a United States sample with predominantly genotype 1a/I chronic hepatitis C liver biopsies correlates with response to IFN therapy. J Interferon Cytokine Res. 1999 Sep; 19(9):1011-8.
    View in: PubMed
    Score: 0.040
  38. Banner BF, Karamitsios N, Smith L, Bonkovsky HL. Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C. Am J Gastroenterol. 1998 Sep; 93(9):1541-5.
    View in: PubMed
    Score: 0.038
  39. Bonkovsky HL. Therapy of hepatitis C: other options. Hepatology. 1997 Sep; 26(3 Suppl 1):143S-151S.
    View in: PubMed
    Score: 0.035
  40. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997 Mar; 25(3):759-68.
    View in: PubMed
    Score: 0.034
  41. O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, Edlin BR, Howell CD, Kirk GD, Kuniholm MH, Morgan TR, Strickler HD, Thomas DL, Prokunina-Olsson L. Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance. J Hepatol. 2015 Nov; 63(5):1103-10.
    View in: PubMed
    Score: 0.030
  42. Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat. 2012 Jun; 19(6):404-13.
    View in: PubMed
    Score: 0.024
  43. O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011; 6(7):e20904.
    View in: PubMed
    Score: 0.023
  44. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May; 140(5):1490-500.e3.
    View in: PubMed
    Score: 0.022
  45. Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol. 2011 May; 106(5):884-93.
    View in: PubMed
    Score: 0.022
  46. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov; 50(5):1360-9.
    View in: PubMed
    Score: 0.020
  47. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL, Shiffman ML, Lindsay KL, Lok AS, Di Bisceglie AM, Lee WM, Ghany MG. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008 Feb; 47(2):605-12.
    View in: PubMed
    Score: 0.018
  48. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR. Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis. Virol J. 2005 Apr 22; 2:41.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.